Analyst Moves: DGX, IVZ
January 31, 2014 at 14:47 PM EST
This morning, UBS decreased its price target on shares of Quest Diagnostics (DGX) to $56 as unusually cold weather will impact the company's first quarter results. In the report, UBS maintained its neutral rating.
